patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.88 [0.83, 0.94]< 1 34% 82 studies (82/-) 100.0 % some concern critical moderate crucial - death or transfer to ICU 0.88 [0.68, 1.13]< 1 0% 5 studies (5/-) 83.8 % some concern not evaluable moderate crucial - deaths 0.86 [0.81, 0.91]< 1 34% 139 studies (139/-) 100.0 % some concern critical moderate crucial 1 deaths (time to event analysis only) 0.82 [0.69, 0.97]< 1 53% 26 studies (26/-) 99.0 % some concern low moderate crucial - clinical deterioration 0.72 [0.60, 0.86]< 1 44% 29 studies (29/-) 100.0 % some concern low moderate important - clinical improvement 1.20 [1.10, 1.30]> 1 42% 39 studies (39/-) 100.0 % some concern critical moderate important - clinical improvement (14-day) 1.37 [1.15, 1.64]> 1 40% 14 studies (14/-) 100.0 % some concern critical moderate important - clinical improvement (21-day) 1.50 [0.22, 10.08]> 1 0% 1 study (1/-) 66.1 % NA not evaluable important - clinical improvement (28-day) 1.59 [1.14, 2.21]> 1 48% 12 studies (12/-) 99.7 % some concern critical moderate important - clinical improvement (7-day) 1.32 [0.90, 1.96]> 1 47% 7 studies (7/-) 92.0 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.12 [1.04, 1.22]> 1 15% 20 studies (20/-) 99.8 % some concern critical moderate important - death or ventilation 0.91 [0.86, 0.96]< 1 52% 30 studies (30/-) 100.0 % some concern critical moderate important - hospital discharge 1.07 [1.01, 1.13]> 1 50% 17 studies (17/-) 98.4 % some concern critical moderate important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 0.87 [0.79, 0.95]< 1 20% 37 studies (37/-) 99.9 % some concern critical moderate important 1 mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 1 0% 2 studies (2/-) 55.5 % some concern not evaluable moderate important - radiologic improvement (14-day) 3.18 [1.91, 5.29]> 1 0% 4 studies (4/-) 100.0 % some concern not evaluable moderate important - Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 1 0% 1 study (1/-) 56.7 % NA not evaluable important - viral clearance 2.60 [1.42, 4.73]> 1 79% 11 studies (11/-) 99.9 % some concern critical moderate important - viral clearance (time to event analysis only) 1.60 [0.92, 2.79]> 1 79% 4 studies (4/-) 95.2 % some concern not evaluable moderate important - viral clearance by day 14 1.38 [0.20, 9.41]> 1 96% 7 studies (7/-) 62.9 % some concern not evaluable moderate important - viral clearance by day 7 1.57 [1.13, 2.18]> 1 58% 9 studies (9/-) 99.6 % some concern serious moderate important - ICU admission 0.79 [0.63, 0.99]< 1 0% 16 studies (16/-) 98.1 % some concern low moderate non important - off oxygenation 1.65 [0.05, 50.02]> 1 81% 2 studies (2/-) 61.1 % high not evaluable low non important - recovery 1.17 [0.98, 1.39]> 1 25% 7 studies (7/-) 96.2 % low not evaluable high non important - 00 composite safety outcome 1.56 [0.78, 3.11]< 1 0% 1 study (1/-) 10.3 % NA not evaluable important - related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - related SAE (TRSAE) 2.04 [0.07, 63.93]< 1 0% 1 study (1/-) 34.4 % NA not evaluable important - serious adverse events 1.04 [0.90, 1.20]< 1 19% 29 studies (29/-) 28.4 % some concern low moderate important - superinfection 0.80 [0.50, 1.27]< 1 61% 5 studies (5/-) 82.9 % some concern not evaluable moderate important - adverse events 1.26 [1.06, 1.49]< 1 14% 24 studies (24/-) 0.4 % some concern low moderate non important -
LoD: level of statistical demonstration:
